Hanmi Pharm. (KRX:128940) posted a 115% year-over-year surge in attributable net income for the second quarter to 83.3 billion won from 38.7 billion won.
Sales surged 29% to 467.2 billion won for the three months ended June 30 from 361.3 billion won, based on a bourse filing on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.